Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PTGX 
Protagonist Therapeutics Inc (PTGX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: PTGX (4-star) is a STRONG-BUY. BUY since 79 days. Simulated Profits (65.88%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $92.83
1 Year Target Price $92.83
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 165.97% | Avg. Invested days 64 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.96B USD | Price to earnings Ratio 144.47 | 1Y Target Price 92.83 |
Price to earnings Ratio 144.47 | 1Y Target Price 92.83 | ||
Volume (30-day avg) 10 | Beta 2.19 | 52 Weeks Range 33.70 - 95.39 | Updated Date 12/14/2025 |
52 Weeks Range 33.70 - 95.39 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.94% | Operating Margin (TTM) -985.17% |
Management Effectiveness
Return on Assets (TTM) 1.82% | Return on Equity (TTM) 7.8% |
Valuation
Trailing PE 144.47 | Forward PE 26.39 | Enterprise Value 5395500753 | Price to Sales(TTM) 28.49 |
Enterprise Value 5395500753 | Price to Sales(TTM) 28.49 | ||
Enterprise Value to Revenue 25.79 | Enterprise Value to EBITDA 248.74 | Shares Outstanding 62515666 | Shares Floating 49893128 |
Shares Outstanding 62515666 | Shares Floating 49893128 | ||
Percent Insiders 1.01 | Percent Institutions 116.03 |
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.protagonist-inc.com |
Full time employees 128 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.